Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 18/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26140150 | 0.89 | ADORA2A (0.40) | ADORA2AADORA2BADORA1 | |
| SCHEMBL24914896 | 0.88 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20400688 | 0.85 | ADORA2A (0.73) | ADORA2AADORA2BADORA1 | |
| SCHEMBL24914973 | 0.85 | ADORA2A (0.75) | ADORA2AADORA2BADORA1 | |
| SCHEMBL24914967 | 0.84 | ADORA2A (0.51) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401637 | 0.83 | ADORA2A (0.60) | ADORA2AADORA2BADORA1 | |
| SCHEMBL30402146 | 0.83 | ADORA2A (0.60) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401194 | 0.81 | ADORA2A (0.46) | ADORA2AADORA2BADORA1 | |
| SCHEMBL26140075 | 0.80 | ADORA2A (0.40) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401236 | 0.80 | ADORA2A (0.62) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.